Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Rheumatology

Standard of Care: Your Roadmap to Remission

At a Glance

The standard treatment for Adult-onset Still's Disease (AOSD) begins with corticosteroids to rapidly stop fevers and inflammation. Doctors often quickly add steroid-sparing drugs like methotrexate or targeted biologics (IL-1 or IL-6 inhibitors) to achieve long-term remission and protect joints.

Managing Adult-onset Still’s Disease (AOSD) is often described as a process of “putting out the fire” and then “keeping the embers from restarting.” Because AOSD is a systemic disease, the treatment must be powerful enough to control body-wide inflammation while minimizing long-term side effects [1][2].

Step 1: Extinguishing the Fire (First-Line Therapy)

The immediate goal of treatment is to stop the high fevers and systemic inflammation as quickly as possible.

  • Corticosteroids: Medications like prednisone are the “cornerstone” of initial treatment [3][4]. They act like a high-volume fire hose, rapidly suppressing the immune system to bring symptoms under control.
  • The Taper: While effective, steroids can have significant side effects if used at high doses for long periods. Current 2024 international consensus guidelines (EULAR/PReS) recommend using steroids for the shortest duration possible to bridge the gap until other medications take effect [2].

Step 2: Steroid-Sparing Agents (Conventional DMARDs)

To help you get off steroids and prevent the “embers” from restarting, your doctor may add a conventional synthetic Disease-Modifying Antirheumatic Drug (csDMARD). These are traditional medications that broadly reduce immune system activity.

  • Methotrexate: This is the most common csDMARD used in AOSD [5]. It is particularly helpful for managing the chronic joint pain (arthritis) that often lingers after the fevers have stopped [6][7].
  • Limitations: While these drugs are helpful for joints, they are often not strong enough on their own to control the intense systemic features (like high fevers or organ involvement) of AOSD [6][8].

Step 3: Targeted Biologics (The Breakthrough Treatments)

If steroids and conventional drugs aren’t enough, or if your symptoms are severe, your doctor will likely move to biologic DMARDs (bDMARDs). Unlike traditional drugs that broadly suppress the immune system, biologics are highly engineered proteins that target the specific “bad actor” cytokines driving the disease [9][10].

Target Common Medications Why It’s Used
IL-1 Inhibitors Anakinra, Canakinumab These target Interleukin-1, a primary driver of AOSD fevers and “cytokine storms” [11][12].
IL-6 Inhibitors Tocilizumab These target Interleukin-6 and are highly effective for both systemic symptoms and persistent joint inflammation [11][13].

Current Consensus Shift: The most recent 2024 guidelines emphasize the early use of IL-1 or IL-6 inhibitors. Starting these biologics sooner rather than later can lead to “clinically inactive disease” (remission) more quickly and help you avoid the long-term side effects of steroids [2][14].

Step 4: Refractory Disease (When First Treatments Fail)

If the first biologic doesn’t work, don’t lose hope. AOSD treatment is flexible, and several other options are available:

  • Switching: Your doctor may switch you from an IL-1 inhibitor to an IL-6 inhibitor (or vice-versa), which often provides a new clinical benefit [15].
  • JAK Inhibitors: Medications like ruxolitinib or baricitinib are emerging options for “refractory” (difficult-to-treat) AOSD [16][17].
  • TNF Inhibitors: Drugs like etanercept or adalimumab may be considered, especially if your symptoms are primarily focused on the joints [9][18].

Important Safety and Monitoring Information

Because all of these medications—from steroids to biologics—work by suppressing parts of your immune system, they carry an increased risk of infections [2]. A simple cold can become serious more quickly. You will need routine blood tests to monitor your liver function, blood counts, and cholesterol while on these therapies [14]. Always report signs of infection (like a new cough, high fever, or painful urination) to your doctor immediately.

Pregnancy Precautions: Certain medications, specifically Methotrexate, are known teratogens, meaning they can cause severe birth defects. Since AOSD often affects young adults, strict birth control is required while on Methotrexate, and it must be stopped well in advance of planning a pregnancy [5]. Consult your rheumatologist regarding family planning before starting these therapies.

Common questions in this guide

Why are steroids prescribed first for Adult-onset Still's Disease?
Steroids like prednisone act rapidly to suppress the immune system and bring intense systemic inflammation and high fevers under control. They are used to bridge the gap until longer-term medications can take effect.
What are biologic therapies for AOSD?
Biologics are engineered proteins that target specific immune signals driving the disease, such as Interleukin-1 (IL-1) or Interleukin-6 (IL-6). These breakthrough treatments often help patients reach remission quickly and reduce the need for long-term steroid use.
Will methotrexate help with my systemic AOSD symptoms?
While methotrexate is very effective at managing chronic joint pain and arthritis associated with AOSD, it is often not strong enough on its own to control intense systemic features like high fevers or organ involvement.
What happens if my first biologic medication doesn't work?
If your initial treatment is ineffective, your doctor has several backup options. They may switch you to a different class of biologic, such as moving from an IL-1 to an IL-6 inhibitor, or prescribe JAK inhibitors or TNF inhibitors.
Can I take methotrexate if I am planning to become pregnant?
No, methotrexate can cause severe birth defects and must be avoided during pregnancy. You should use strict birth control while on this medication and consult your rheumatologist well before planning to start a family.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the 2024 EULAR consensus, should we consider starting an IL-1 or IL-6 inhibitor early in my treatment to minimize my total steroid exposure?
  2. 2.What is my target date for starting a prednisone taper, and what is our plan if symptoms return during the taper?
  3. 3.If my systemic symptoms (like fever) are controlled but my joint pain (arthritis) persists, would adding methotrexate be beneficial?
  4. 4.Are there specific reasons to choose an IL-1 inhibitor (like Anakinra) over an IL-6 inhibitor (like Tocilizumab) for my specific case?
  5. 5.If my first biologic doesn't work, what is the next step in our 'switching' strategy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    [Adult-onset Still's disease : Rare adult-onset autoinflammatory syndrome].

    Oms E, Tronnier M

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2019; (70(7)):530-534 doi:10.1007/s00105-019-4394-8.

    PMID: 30937478
  2. 2

    EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.

    Fautrel B, Mitrovic S, De Matteis A, et al.

    Annals of the rheumatic diseases 2024; (83(12)):1614-1627 doi:10.1136/ard-2024-225851.

    PMID: 39317417
  3. 3

    Challenges on diagnosis and treatment of refractory adult-onset still disease in Sub-Saharan Africa: a case report.

    Simeni Njonnou SR, Kemta Lekpa F, Essoka Essoka AR, et al.

    Journal of medical case reports 2025; (19(1)):472 doi:10.1186/s13256-025-05477-8.

    PMID: 41029705
  4. 4

    Adult-onset Still's Disease: A Case Report.

    Karki B, K C N, Mahato AK, et al.

    JNMA; journal of the Nepal Medical Association 2023; (61(264)):662-664 doi:10.31729/jnma.8237.

    PMID: 38289815
  5. 5

    Delayed diagnosis of adult onset Still's disease in 2 cases: diagnostic dilemma in positive antinuclear antibody and tuberculosis endemic areas.

    Rahman PA, Sakti PT

    Postgraduate medicine 2025; (137(1)):100-107 doi:10.1080/00325481.2024.2433930.

    PMID: 39588906
  6. 6

    Perspectives on the use of non-biological pharmacotherapy for adult-onset Still's disease.

    Di Cola I, Cipriani P, Ruscitti P

    Expert opinion on pharmacotherapy 2022; (23(14)):1577-1587 doi:10.1080/14656566.2022.2126764.

    PMID: 36124816
  7. 7

    The effectiveness of tocilizumab in treating refractory adult-onset Still's disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response.

    Tang KT, Hsieh CW, Chen HH, et al.

    Clinical rheumatology 2022; (41(2)):557-566 doi:10.1007/s10067-021-05921-2.

    PMID: 34535869
  8. 8

    Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.

    Sfriso P, Bindoli S, Galozzi P

    Drugs 2018; (78(12)):1187-1195 doi:10.1007/s40265-018-0956-9.

    PMID: 30069732
  9. 9

    Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review.

    Wang MY, Jia JC, Yang CD, Hu QY

    Chinese medical journal 2019; (132(23)):2856-2864 doi:10.1097/CM9.0000000000000538.

    PMID: 31856058
  10. 10

    Current and emerging biological therapy in adult-onset Still's disease.

    Ma Y, Meng J, Jia J, et al.

    Rheumatology (Oxford, England) 2021; (60(9)):3986-4000 doi:10.1093/rheumatology/keab485.

    PMID: 34117886
  11. 11

    Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.

    Bindoli S, De Matteis A, Mitrovic S, et al.

    Annals of the rheumatic diseases 2024; (83(12)):1731-1747 doi:10.1136/ard-2024-225854.

    PMID: 39317415
  12. 12

    [Adult-onset Still's disease : Diagnosis and treatment according to the new S2e guidelines of the German Society of Rheumatology (DGRh)].

    Vordenbäumen S, Feist E

    Zeitschrift fur Rheumatologie 2023; (82(2)):134-142 doi:10.1007/s00393-022-01293-3.

    PMID: 36515738
  13. 13

    Tocilizumab combined with short-term high-dose glucocorticoids for rapid disease activity control and glucocorticoid reduction in adult-onset Still's disease: a single-center retrospective study.

    Zhong SL, Lei YP, Zhou LX, et al.

    Frontiers in immunology 2026; (17()):1732826 doi:10.3389/fimmu.2026.1732826.

    PMID: 41727458
  14. 14

    Early IL-1 Inhibition in Still's Disease: A Window of Opportunity for Improving Outcomes.

    Bindoli S, Cadore C, Guidea I, et al.

    ACR open rheumatology 2025; (7(10)):e70106 doi:10.1002/acr2.70106.

    PMID: 41040000
  15. 15

    Current evidence on switching between biologic therapies for Still's disease: A systematic literature review.

    Dagna L, Feist E, Horneff G, et al.

    Seminars in arthritis and rheumatism 2025; (74()):152789 doi:10.1016/j.semarthrit.2025.152789.

    PMID: 40738082
  16. 16

    The efficacy and safety of JAK inhibitors in patients with adult-onset still's disease: A meta-analysis and systematic review.

    Liao J, Tang Q, Xie X, et al.

    International immunopharmacology 2024; (137()):112451 doi:10.1016/j.intimp.2024.112451.

    PMID: 38870881
  17. 17

    JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.

    Gillard L, Pouchot J, Cohen-Aubart F, et al.

    Rheumatology (Oxford, England) 2023; (62(4)):1594-1604 doi:10.1093/rheumatology/keac440.

    PMID: 35920788
  18. 18

    Refractory Adult-onset Still's Disease Treated with a Combination of Methotrexate and Etanercept.

    El Hasbani G, Ahmad Y, Cassetta M

    Current rheumatology reviews 2024; (20(2)):219-222 doi:10.2174/0115733971244440230921100912.

    PMID: 37855287

This page explains standard treatments for Adult-onset Still's disease for educational purposes. Always consult your rheumatologist to determine the safest and most effective medication plan for your specific symptoms.

Get notified when new evidence is published on Adult-onset Still disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.